中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:249 更新时间:2025-05-18
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!将品牌入驻外推网,定制中生北控BioSino品牌推广信息,可以显著提高中生北控BioSino产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

广州房贷利率今起上调10BP,多银行已执行

从部分银行及房产中介获悉,5月17日起,广州地区银行首套房贷利率从原来的LPR-60bp调整为LPR-50bp,即五年期以上首套房贷利率涨10BP,由原来的3.0%上调到3.1%。有房产中介人士5月7日透露,合作银行已将房贷利率统一上调10BP,今天起,项目给客户算的价格,已经按照3.1%的房贷利率来算了。有市场人士表示,此次房贷利率加点的上调,或是对冲20号LPR下降的。银行此举或是为了遵守房贷利率3.0%的下限。(广州日报)

41分钟前

中科金财:公司多模态技术在微短剧、视觉智算及数字人等领域落地应用

中科金财在“投资者走进中科金财活动”表示,公司多模态技术在微短剧、视觉智算及数字人等领域落地应用。在微短剧领域,公司与快手联合出品微短剧《浮梦吟》,公司为该剧提供AI技术服务。公司研发了基于视觉理解大模型的多模态智能体,可以理解分析视频内容,并提供智能剪辑、智能翻译、智能发布等全链路AI创作和分发工具。(证券时报)

41分钟前

张朝阳谈AI发展:科技进步带来惊喜和挑战,人类要时刻保持清醒

36氪获悉,5月17日“世界电信日”当天,2025搜狐科技年度论坛在北京举办,多位院士、科学家与产业界人士出席。搜狐创始人、董事局主席兼首席执行官、物理学博士张朝阳在致辞中表示,进入2024年、2025年,人类关于AI方面的进展进入快车道,具身智能百花齐放。但是,科技进步带来惊喜,同样也带来挑战。同时他强调,AI让信息获取变得异常简单,但往往会让人忽略信息的真实性,人们必须时刻保持清醒。

41分钟前

禁用AI代写作业,教育部规范推进中小学AI教育

近日,《中小学人工智能通识教育指南(2025年版)》和《中小学生成式人工智能使用指南(2025年版)》正式发布。其中明确,禁止学生直接复制人工智能生成内容作为作业或考试答案,并禁止小学阶段学生独自使用开放式内容生成功能。同时该指南强调,教师不得将生成式人工智能作为替代性教学主体。(21财经)

41分钟前

中信证券:管理软件或是AI Agent落地最佳场景之一

36氪获悉,中信证券研报称,2025年有望成为AI应用落地的元年,AI Agent应用场景有望迎来快速爆发。管理软件或是AI Agent落地的最佳场景之一,具备长期行业积累的传统行业龙头公司具备显著优势。短期产品价值逻辑验证和产业技术变革有望带来新催化,而从Q4开始AI应用收入有望在各公司业绩上有所显现,带动新一轮公司价值重估。建议持续关注AI在财务、人力、销售、生产、供应链等管理软件核心模块上的商业进展,优先关注企业服务细分领域龙头的投资机会。

41分钟前

本页详细列出关于中生北控BioSino的品牌信息,含品牌所属公司介绍,中生北控BioSino所处行业的品牌地位及优势。
咨询